Multimodal Imaging of 2-Cycle PRRT with
Animals
Cell Line, Tumor
Cell Transformation, Neoplastic
Coordination Complexes
/ therapeutic use
Humans
Magnetic Resonance Imaging
Mice
Multimodal Imaging
Neuroendocrine Tumors
/ diagnostic imaging
Octreotide
/ analogs & derivatives
Peptides, Cyclic
/ therapeutic use
Positron-Emission Tomography
Receptors, Peptide
/ metabolism
Single Photon Emission Computed Tomography Computed Tomography
177Lu-DOTA-JR11
PET/MRI
SPECT/CT
multimodal imaging
peptide receptor radionuclide therapy
somatostatin receptor antagonist
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
27
05
2020
accepted:
09
07
2020
pubmed:
30
8
2020
medline:
30
4
2021
entrez:
30
8
2020
Statut:
ppublish
Résumé
Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin receptor (SSTR) analogs is a common approach in advanced neuroendocrine neoplasms. Recently, SSTR antagonists have shown promising results for imaging and therapy due to a higher number of binding sites than in commonly used agonists. We evaluated PRRT with SSTR agonist
Identifiants
pubmed: 32859703
pii: jnumed.120.250274
doi: 10.2967/jnumed.120.250274
pmc: PMC8049340
doi:
Substances chimiques
177Lu-octreotide, DOTA(0)-Tyr(3)-
0
Coordination Complexes
0
Peptides, Cyclic
0
Receptors, Peptide
0
177Lu-DOTA-JR11
CAX3X53UL6
Octreotide
RWM8CCW8GP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
393-398Informations de copyright
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.
Références
Contrast Media Mol Imaging. 2019 Jan 3;2019:6438196
pubmed: 30733648
Neuroendocrinology. 2016;103(2):153-71
pubmed: 26742109
J Nucl Med. 2008 Jan;49(1):151-7
pubmed: 18077517
BMC Cancer. 2012 Dec 05;12:579
pubmed: 23217114
J Nucl Med. 2016 Feb;57(2):260-5
pubmed: 26514177
EJNMMI Res. 2019 Feb 22;9(1):21
pubmed: 30796555
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Cancer Res. 2019 Aug 1;79(15):3952-3964
pubmed: 31186232
Theranostics. 2019 Sep 19;9(22):6719-6733
pubmed: 31588246
J Nucl Med. 2011 Sep;52(9):1412-7
pubmed: 21852357
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16436-41
pubmed: 17056720
Cancer Treat Rev. 2018 Dec;71:39-46
pubmed: 30352319
J Nucl Med. 2017 Sep;58(9):1435-1441
pubmed: 28450554
Neuroendocrinology. 2016;103(2):172-85
pubmed: 26731013
J Nucl Med. 2014 Aug;55(8):1248-52
pubmed: 24963127
Nat Rev Endocrinol. 2009 Jul;5(7):382-93
pubmed: 19488074
J Nucl Med. 2012 Sep;53(9):1481-9
pubmed: 22851637
Theranostics. 2016 Feb 13;6(4):501-10
pubmed: 26941843
Front Endocrinol (Lausanne). 2018 Apr 06;9:146
pubmed: 29681888
EJNMMI Res. 2016 Dec;6(1):50
pubmed: 27294582
Clin Cancer Res. 2019 Dec 1;25(23):6939-6947
pubmed: 31439583